JP7183163B2 - プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 - Google Patents

プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 Download PDF

Info

Publication number
JP7183163B2
JP7183163B2 JP2019536937A JP2019536937A JP7183163B2 JP 7183163 B2 JP7183163 B2 JP 7183163B2 JP 2019536937 A JP2019536937 A JP 2019536937A JP 2019536937 A JP2019536937 A JP 2019536937A JP 7183163 B2 JP7183163 B2 JP 7183163B2
Authority
JP
Japan
Prior art keywords
single domain
domain antibody
binding
human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019536937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515235A (ja
JP2020515235A5 (enExample
Inventor
ブライアン・エドワーズ
キャロリン・エドワーズ
ジェームズ・レッグ
マルティナ・レヴァンドフスカ
ダニエラ・シドレク
コレット・ジョンストン
クリスティーン・ロサント
ユミン・テン
Original Assignee
クレシェンド・バイオロジックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1700207.2A external-priority patent/GB201700207D0/en
Priority claimed from GBGB1700210.6A external-priority patent/GB201700210D0/en
Priority claimed from GBGB1700208.0A external-priority patent/GB201700208D0/en
Application filed by クレシェンド・バイオロジックス・リミテッド filed Critical クレシェンド・バイオロジックス・リミテッド
Publication of JP2020515235A publication Critical patent/JP2020515235A/ja
Publication of JP2020515235A5 publication Critical patent/JP2020515235A5/ja
Priority to JP2022158582A priority Critical patent/JP7525567B2/ja
Application granted granted Critical
Publication of JP7183163B2 publication Critical patent/JP7183163B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Food Science & Technology (AREA)
JP2019536937A 2017-01-06 2018-01-08 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 Active JP7183163B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022158582A JP7525567B2 (ja) 2017-01-06 2022-09-30 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1700210.6 2017-01-06
GBGB1700207.2A GB201700207D0 (en) 2017-01-06 2017-01-06 Single domain antibodies to prgrammed cell death (PD-1)
GBGB1700210.6A GB201700210D0 (en) 2017-01-06 2017-01-06 Single domain antibodies to programmed cell death (PD-1)
GBGB1700208.0A GB201700208D0 (en) 2017-01-06 2017-01-06 Single domain antibodies to programmed cell death (PD-1)
GB1700208.0 2017-01-06
GB1700207.2 2017-01-06
PCT/GB2018/050035 WO2018127709A1 (en) 2017-01-06 2018-01-08 Single domain antibodies to programmed cell death (pd-1)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022158582A Division JP7525567B2 (ja) 2017-01-06 2022-09-30 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体

Publications (3)

Publication Number Publication Date
JP2020515235A JP2020515235A (ja) 2020-05-28
JP2020515235A5 JP2020515235A5 (enExample) 2021-02-18
JP7183163B2 true JP7183163B2 (ja) 2022-12-05

Family

ID=60953895

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019536936A Active JP7267921B2 (ja) 2017-01-06 2018-01-08 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
JP2019536937A Active JP7183163B2 (ja) 2017-01-06 2018-01-08 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
JP2022158582A Active JP7525567B2 (ja) 2017-01-06 2022-09-30 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
JP2022177574A Pending JP2023010753A (ja) 2017-01-06 2022-11-04 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019536936A Active JP7267921B2 (ja) 2017-01-06 2018-01-08 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022158582A Active JP7525567B2 (ja) 2017-01-06 2022-09-30 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
JP2022177574A Pending JP2023010753A (ja) 2017-01-06 2022-11-04 プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体

Country Status (5)

Country Link
US (5) US11814429B2 (enExample)
EP (3) EP3565841A1 (enExample)
JP (4) JP7267921B2 (enExample)
CN (2) CN110167966B (enExample)
WO (3) WO2018127709A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022191316A (ja) * 2017-01-06 2022-12-27 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
KR20200080304A (ko) 2017-11-13 2020-07-06 크레센도 바이오로직스 리미티드 Cd137에 결합하는 단일 도메인 항체
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
EP3864049A1 (en) * 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
EP3882269A4 (en) * 2018-11-16 2022-10-12 Nanjing GenScript Biotech Co., Ltd. HUMANIZED MONOCLONAL ANTI-HUMAN PD-L1 ANTIBODY, METHOD OF PRODUCTION THEREOF AND USE THEREOF
CN120623341A (zh) * 2019-03-22 2025-09-12 反射制药有限公司 用于目标蛋白的多价d-肽化合物
CN110003336B (zh) * 2019-04-12 2023-05-12 深圳普瑞金生物药业股份有限公司 Pd-1单域抗体、核苷酸序列及试剂盒
JP2022530496A (ja) * 2019-04-26 2022-06-29 ウーシー バイオロジクス アイルランド リミテッド Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体
EP3733708A1 (en) * 2019-05-02 2020-11-04 Randox Laboratories Ltd Immune checkpoint molecule inhibitor
US20220227850A1 (en) * 2019-05-15 2022-07-21 Crescendo Biologics Limited Binding molecules
BR112022003163A2 (pt) * 2019-08-19 2022-05-17 Pandion Operations Inc Imunotolerância alvejada com um agonista de pd-1
CN112409483B (zh) * 2019-08-22 2024-08-27 浙江道尔生物科技有限公司 抗pd-l1纳米抗体
JP7445752B2 (ja) * 2019-09-25 2024-03-07 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－ｌ１抗体
CN110950956B (zh) * 2019-12-12 2022-03-08 源道隆（苏州）医学科技有限公司 可结合pd1的多肽及其应用
KR20220160670A (ko) * 2020-03-31 2022-12-06 바이오세우스 인크. 항 pd-l1 및 pd-l2 항체 및 이의 유도체 및 용도
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
WO2022068919A1 (zh) * 2020-09-30 2022-04-07 正大天晴康方(上海)生物医药科技有限公司 结合pd-1抗体的肽及其应用
CN114685655B (zh) * 2020-12-28 2024-04-12 浙江纳米抗体技术中心有限公司 Pd-1结合分子及其应用
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
KR20230163503A (ko) * 2021-03-31 2023-11-30 메뤼스 엔.페. 신규한 pd-1 결합 도메인
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
GB202205589D0 (en) * 2022-04-14 2022-06-01 Crescendo Biologics Ltd Mesothelin binders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP2013521769A (ja) 2010-03-11 2013-06-13 ユセベ ファルマ ソシエテ アノニム 生物学的製剤：ヒト化アゴニスト抗ｐｄ−１抗体
WO2016020856A2 (en) 2014-08-05 2016-02-11 MabQuest SA Immunological reagents
WO2016062990A1 (en) 2014-10-22 2016-04-28 Crescendo Biologics Limited Transgenic mice
WO2016106159A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113120D0 (en) * 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
US7989594B2 (en) * 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
DK1851250T3 (da) 2005-02-18 2012-07-09 Medarex Inc Humant monoklonalt antistof mod prostataspecifikt membranantigen (psma)
BRPI0614475B8 (pt) 2005-08-03 2021-05-25 Fraunhofer Usa Inc polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
CA2718705A1 (en) 2008-03-17 2009-09-24 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
CA2790134A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
EP2646467A2 (en) 2010-12-01 2013-10-09 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
KR20140127816A (ko) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
US20130302250A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
CN103087171B (zh) 2012-12-24 2015-01-14 中国人民解放军第四军医大学 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
CN103333249A (zh) 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
AU2014315457B2 (en) * 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20150201768A1 (en) 2014-01-22 2015-07-23 Thomas J. Bower Dining napkin with special perforation feature
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR20150089702A (ko) 2014-01-28 2015-08-05 제일모직주식회사 신규 화합물, 신규 폴리머, 이를 포함하는 착색제, 이를 포함하는 감광성 수지 조성물 및 컬러필터
PT3556775T (pt) 2014-01-28 2021-12-31 Bristol Myers Squibb Co Anticorpos anti-lag-3 para tratar neoplasias malignas hematológicas
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
HUE052223T2 (hu) 2014-04-25 2021-04-28 Pf Medicament IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
US11275080B2 (en) 2014-11-05 2022-03-15 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block PD1/PDL1 axis
RS64002B1 (sr) 2015-05-18 2023-03-31 Pieris Pharmaceuticals Gmbh Anti-kancerski fuzioni polipeptid
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
SG10202010506TA (en) 2015-07-30 2020-11-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
RU2018116402A (ru) 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора
KR102220275B1 (ko) 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
BR112018013677A2 (pt) 2016-01-11 2019-01-22 Inhibrx Inc proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
US11236174B2 (en) 2016-01-12 2022-02-01 Crescendo Biologics Limited Therapeutic molecules
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3565841A1 (en) * 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CA3052291A1 (en) 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3425763B1 (en) 2017-07-03 2020-11-18 France Brevets Coupling interface and method of operation
TWI875679B (zh) 2017-07-06 2025-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
KR20200080304A (ko) 2017-11-13 2020-07-06 크레센도 바이오로직스 리미티드 Cd137에 결합하는 단일 도메인 항체
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
GB201818460D0 (en) 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
US20220227850A1 (en) 2019-05-15 2022-07-21 Crescendo Biologics Limited Binding molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP2013521769A (ja) 2010-03-11 2013-06-13 ユセベ ファルマ ソシエテ アノニム 生物学的製剤：ヒト化アゴニスト抗ｐｄ−１抗体
WO2016020856A2 (en) 2014-08-05 2016-02-11 MabQuest SA Immunological reagents
WO2016062990A1 (en) 2014-10-22 2016-04-28 Crescendo Biologics Limited Transgenic mice
WO2016106159A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU GENG，SINGLE DOMAIN ANTIBODIES AGAINST IMMUNE CHECKPOINT TARGETS PD-1 AND PD-L1，IMMUNOME RESEARCH，2016年12月，V12 N2 (SUPPL)，P47，https://www.longdom.org/proceedings/single-doman-antibodies-against-immune-checkpoint-targets-pd1-and-pdl1-6861.html，2ND INTERNATIONAL CONFERENCE ON ANTIBODIES AND THERAPEUTICS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022191316A (ja) * 2017-01-06 2022-12-27 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
JP7525567B2 (ja) 2017-01-06 2024-07-30 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体

Also Published As

Publication number Publication date
US20230357405A1 (en) 2023-11-09
US20220306744A1 (en) 2022-09-29
EP3565840A1 (en) 2019-11-13
US11591398B2 (en) 2023-02-28
EP3565842A1 (en) 2019-11-13
JP2020515235A (ja) 2020-05-28
CN110167966A (zh) 2019-08-23
CN110167966B (zh) 2024-08-30
US20200239573A1 (en) 2020-07-30
US20200239570A1 (en) 2020-07-30
WO2018127709A1 (en) 2018-07-12
WO2018127711A1 (en) 2018-07-12
EP3565841A1 (en) 2019-11-13
JP7267921B2 (ja) 2023-05-02
WO2018127710A1 (en) 2018-07-12
US11814429B2 (en) 2023-11-14
CN110121510A (zh) 2019-08-13
JP2023010753A (ja) 2023-01-20
JP7525567B2 (ja) 2024-07-30
US11312771B2 (en) 2022-04-26
JP2020503870A (ja) 2020-02-06
US20190322749A1 (en) 2019-10-24
CN110121510B (zh) 2024-06-11
JP2022191316A (ja) 2022-12-27

Similar Documents

Publication Publication Date Title
JP7525567B2 (ja) プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
JP7312168B2 (ja) Ｃｄ１３７に結合するシングルドメイン抗体
US20240350651A1 (en) Therapeutic molecules that bind to lag3 and pd1
US20240254231A1 (en) Therapeutic antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220930

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221007

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221122

R150 Certificate of patent or registration of utility model

Ref document number: 7183163

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150